LearnGlossaryMarketStocksSuperinvestorsSign in

SRRK

Scholar Rock Holding Corporation

Healthcare · $6.5B market cap

Verdict

We can't put a fair value on SRRK right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-15.0% a year✗
Sales growth19.8% a year✓
Free cash flow growth—?
Return on invested capital-52.9%✗

Follow SRRK

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds SRRK. In Q1 2026, 1 added. Who we track

Polen Capital Management

Polen Capital Management · as of Q2 2026

$2.9M

52,132 shares

Moves in Q1 2026

Added: Polen Capital Management

About Scholar Rock Holding Corporation

Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works